Clinical trial
Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel)…
NCT00332332 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00332332 |
|---|---|
| Title | Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis |
| Official title | Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel (Etanercept) in Psoriasis |
| Lead sponsor | Amgen, Industry |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Biological |
| Interventions | etanercept |
| Enrollment | 246 |
| Start date | Mar 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Feb 1, 2010 |
| First posted | Jun 1, 2006 |
| Last update posted | Jul 25, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: